Statistics for Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector
Total visits
| views | |
|---|---|
| Cost utility analysis of long acting muscarinic antagonists (LAMAs) as an alternative to long acting beta agonists (labas) for treatment of severe COPD in the South African public sector | 26 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 2 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| MPH_COMH7175A_1946476_03.06.2023.pdf | 113 |
Top country views
| views | |
|---|---|
| South Africa | 21 |
| Tanzania | 2 |
| Norway | 1 |
Top city views
| views | |
|---|---|
| Johannesburg | 17 |
| Dar es Salaam | 2 |
| Lenasia | 2 |
| Pretoria | 1 |